Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.5%

2 terminated/withdrawn out of 21 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

47%

7 of 15 completed trials have results

Key Signals

3 recruiting7 with results

Enrollment Performance

Analytics

Phase 1
12(63.2%)
N/A
4(21.1%)
Phase 2
2(10.5%)
Phase 3
1(5.3%)
19Total
Phase 1(12)
N/A(4)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT05890963Phase 1Active Not Recruiting

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

Role: collaborator

NCT02761200Recruiting

Post Analytic Treatment Interruption Study

Role: collaborator

NCT05423418Phase 1Completed

Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults

Role: collaborator

NCT05797961Not ApplicableCompleted

HIV Self-testing With Online Supervision for Vietnamese MSM

Role: collaborator

NCT07217379Phase 1Recruiting

The DART DELIVER-02 Study

Role: collaborator

NCT06484335Phase 1Recruiting

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Role: collaborator

NCT00622843Phase 3Completed

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

Role: collaborator

NCT04826094Phase 1Completed

A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

Role: collaborator

NCT02315703Phase 1Completed

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Role: collaborator

NCT03307915Phase 1Completed

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Role: collaborator

NCT05769569Phase 1Withdrawn

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

Role: collaborator

NCT01791556Not ApplicableCompleted

Clinic-based ART Diagnostic Evaluation

Role: collaborator

NCT00631566Not ApplicableCompleted

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

Role: collaborator

NCT04041570Phase 1Completed

Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

Role: collaborator

NCT03884816Completed

HIV and STIs Clinical Study in Germany

Role: collaborator

NCT03475056Phase 1Completed

cAd3-Marburg Vaccine in Healthy Adults

Role: collaborator

NCT00498056Phase 2Withdrawn

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

Role: collaborator

NCT02218125Phase 1Completed

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

Role: collaborator

NCT02354404Phase 1Completed

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

Role: collaborator

NCT02614950Not ApplicableCompleted

Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection

Role: collaborator